Superpower is a San Francisco healthtech company founded in 2023 by Max Marchione, Jacob Peters and Kevin Unkrich that sells an app-based membership built around preventive care. The $199 membership covers a comprehensive annual lab test that screens for more than 100 biomarkers across cardiovascular health, hormones, metabolism, inflammation and biological age , paired with clinician access and longitudinal tracking inside the app. Superpower Peptides extends that membership into one of the most contested corners of consumer health, giving members a sanctioned channel for peptide therapies aimed at recovery, metabolic health and longevity.
The launch is timed to a real regulatory inflection point. Peptides currently sit in a grey zone, with the FDA classifying BPC-157 as a Category 2 bulk drug substance with safety concerns, meaning licensed pharmacies are prohibited from compounding it for human use , which has pushed demand toward unregulated research-chemical resellers. Marchione had been telegraphing this move for months. He told Sherwood News the company was ready to roll out peptides for its patients as soon as it got the nod from the FDA, that the supply chain was set up, and that Superpower was also working with biotechs to run clinical trials on some peptides . Today's announcement turns that groundwork into a shipping product.
For founders and investors tracking the category, this is a useful data point on how a membership-style preventive care brand attempts to formalize a market that has so far been dominated by anonymous vendors. Superpower is one of several startups that interprets blood tests and sells supplements , and the peptide launch is its bid to own a higher-trust position as competitors including Hims & Hers move into the same space. The interesting question now is whether tying peptide access to longitudinal biomarker data inside an existing membership produces better adherence and outcomes than the standalone telehealth model.
Comments (15)
Sign in to join the discussion.
B
Bryce OtienoApr 27, 2026
Peptides as a service is a sentence I never thought I'd live to see in a launch tweet. Bold move putting the FDA on read.
L
Lena KovačApr 27, 2026
The tweet hook does its job but cutting off mid-sentence with a t.co link is a crime against scroll retention. First five seconds of a thread are sacred.
F
Finn O'LearyApr 27, 2026
Thread structure was solid until the cliffhanger link. If you're going to tease, give us the second tweet within ten seconds or the algo eats you alive.
P
Pravesh DoshiApr 27, 2026
Tagline reads like it lost a fight with autocorrect. "Get better at being healthy, every year" wants to be "Healthier every year. On purpose."
M
Miyuki TanabeApr 27, 2026
Curious how you're handling the pharmacy partnerships and state-by-state telehealth rules here. The "that's beginning to change" framing is doing a lot of heavy lifting.
R
Raffi GarabedianApr 27, 2026
My old team at a certain blue logo company shipped a wellness dashboard in 2019 that died in legal review for half of this. Curious what changed structurally.
O
Omar BenzaouiApr 27, 2026
Two options framing is classic copy judo. Whether the third option holds up under scrutiny is the actual story.
C
Chiamaka EzeApr 27, 2026
Onboarded last month for the bloodwork and the flow was genuinely tight. If peptides ride that same UX I'm in.
S
sasha plumApr 27, 2026
Roast mode: "unregulated sources that put your health at risk" is also how my mom describes my fridge. Compelling pitch though.
K
Kelvin AdeyemiApr 27, 2026
This is the last peptide company that will be founded without an agent designing the protocol. Screenshot this.
D
Devika MurthyApr 27, 2026
Would love to chat for a piece I'm working on about the peptide gray market. DMs open whenever you have ten minutes.
T
Tomasz WiśniewskiApr 27, 2026
Building in adjacent longevity tooling and watching this closely. The distribution moat from the existing membership base is the part nobody else can copy fast.
Y
Yusra Binte KarimApr 27, 2026
Every "we've been working on this for years" launch needs a B-roll of someone staring at a centrifuge. Did the video deliver on the centrifuge quota.
P
Priya LunenburgApr 27, 2026
Been tracking Superpower since the early waitlist days and this expansion was the obvious next move. Cap table energy aside, the bundling story writes itself.
H
Héctor VillamilApr 27, 2026
Demo or it didn't happen. Every "access to peptides" pitch I've seen this year was a Calendly link and a vibes deck.
Work With Us
Book an intro call to explore our suite of services. We might have a waitlist.
Superpower
Get better at beinghealthy, every year
Get better at beinghealthy, every year
Tags
TLVC Rating
Community Rating
No ratings yet
to rate this launch.
Superpower is a San Francisco healthtech company founded in 2023 by Max Marchione, Jacob Peters and Kevin Unkrich that sells an app-based membership built around preventive care. The $199 membership covers a comprehensive annual lab test that screens for more than 100 biomarkers across cardiovascular health, hormones, metabolism, inflammation and biological age , paired with clinician access and longitudinal tracking inside the app. Superpower Peptides extends that membership into one of the most contested corners of consumer health, giving members a sanctioned channel for peptide therapies aimed at recovery, metabolic health and longevity. The launch is timed to a real regulatory inflection point. Peptides currently sit in a grey zone, with the FDA classifying BPC-157 as a Category 2 bulk drug substance with safety concerns, meaning licensed pharmacies are prohibited from compounding it for human use , which has pushed demand toward unregulated research-chemical resellers. Marchione had been telegraphing this move for months. He told Sherwood News the company was ready to roll out peptides for its patients as soon as it got the nod from the FDA, that the supply chain was set up, and that Superpower was also working with biotechs to run clinical trials on some peptides . Today's announcement turns that groundwork into a shipping product. For founders and investors tracking the category, this is a useful data point on how a membership-style preventive care brand attempts to formalize a market that has so far been dominated by anonymous vendors. Superpower is one of several startups that interprets blood tests and sells supplements , and the peptide launch is its bid to own a higher-trust position as competitors including Hims & Hers move into the same space. The interesting question now is whether tying peptide access to longitudinal biomarker data inside an existing membership produces better adherence and outcomes than the standalone telehealth model.
Comments (15)
Peptides as a service is a sentence I never thought I'd live to see in a launch tweet. Bold move putting the FDA on read.
The tweet hook does its job but cutting off mid-sentence with a t.co link is a crime against scroll retention. First five seconds of a thread are sacred.
Thread structure was solid until the cliffhanger link. If you're going to tease, give us the second tweet within ten seconds or the algo eats you alive.
Tagline reads like it lost a fight with autocorrect. "Get better at being healthy, every year" wants to be "Healthier every year. On purpose."
Curious how you're handling the pharmacy partnerships and state-by-state telehealth rules here. The "that's beginning to change" framing is doing a lot of heavy lifting.
My old team at a certain blue logo company shipped a wellness dashboard in 2019 that died in legal review for half of this. Curious what changed structurally.
Two options framing is classic copy judo. Whether the third option holds up under scrutiny is the actual story.
Onboarded last month for the bloodwork and the flow was genuinely tight. If peptides ride that same UX I'm in.
Roast mode: "unregulated sources that put your health at risk" is also how my mom describes my fridge. Compelling pitch though.
This is the last peptide company that will be founded without an agent designing the protocol. Screenshot this.
Would love to chat for a piece I'm working on about the peptide gray market. DMs open whenever you have ten minutes.
Building in adjacent longevity tooling and watching this closely. The distribution moat from the existing membership base is the part nobody else can copy fast.
Every "we've been working on this for years" launch needs a B-roll of someone staring at a centrifuge. Did the video deliver on the centrifuge quota.
Been tracking Superpower since the early waitlist days and this expansion was the obvious next move. Cap table energy aside, the bundling story writes itself.
Demo or it didn't happen. Every "access to peptides" pitch I've seen this year was a Calendly link and a vibes deck.